These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15006394)

  • 1. Synthesis of a novel nitroimidazole-spermidine derivative as a tumor-targeted hypoxia-selective cytotoxin.
    Papadopoulou MV; Rosenzweig HS; Bloomer WD
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1519-22. PubMed ID: 15006394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore.
    Papadopoulou MV; Bloomer WD
    Anticancer Drugs; 2009 Jul; 20(6):493-502. PubMed ID: 19430289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NLNQ-1, a 2-[3-(2-nitro-1-imidazolyl) propylamino]-3-chloro-1,4-naphthoquinone, as a hypoxia-selective cytotoxin and radiosensitizer.
    Papadopoulou MV; Bloomer WD
    In Vivo; 2008; 22(3):285-8. PubMed ID: 18610737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-1,2,3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1.
    Papadopoulou MV; Rosenzweig HS; Doddi M; Bloomer WD
    Oncol Res; 1994; 6(9):439-48. PubMed ID: 7703530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel fluorinated hypoxia-targeted compounds as Non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS).
    Papadopoulou MV; Ji M; Bloomer WD
    Anticancer Res; 2006; 26(5A):3253-8. PubMed ID: 17094437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
    Papadopoulou MV; Rosenzweig HS; Bloomer WD
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1523-5. PubMed ID: 15006395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as chemosensitizer: mechanistic studies. II.
    Papadopoulou MV; Rosenzweig HS; Ji M; Khan SH; Bloomer WD
    Oncol Res; 1998; 10(3):163-73. PubMed ID: 9700727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers.
    Bonnet M; Hong CR; Gu Y; Anderson RF; Wilson WR; Pruijn FB; Wang J; Hicks KO; Hay MP
    Bioorg Med Chem; 2014 Apr; 22(7):2123-32. PubMed ID: 24650701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis inhibitor TX-1898: syntheses of the enantiomers of sterically diverse haloacetylcarbamoyl-2-nitroimidazole hypoxic cell radiosensitizers.
    Jin CZ; Nagasawa H; Shimamura M; Uto Y; Inayama S; Takeuchi Y; Kirk KL; Hori H
    Bioorg Med Chem; 2004 Sep; 12(18):4917-27. PubMed ID: 15336271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility.
    Hay MP; Lee HH; Wilson WR; Roberts PB; Denny WA
    J Med Chem; 1995 May; 38(11):1928-41. PubMed ID: 7783125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake and cytotoxicity of novel nitroimidazole-polyamine conjugates in Ehrlich ascites tumour cells.
    Holley J; Mather A; Cullis P; Symons MR; Wardman P; Watt RA; Cohen GM
    Biochem Pharmacol; 1992 Feb; 43(4):763-9. PubMed ID: 1540230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, transportability and hypoxiaselective binding of 1-beta-D-(5-Deoxy-5-fluororibofuranosyl)-2-nitroimidazole (beta-5-FAZR), a configurational isomer of the clinical hypoxia marker, FAZA.
    Emami S; Kumar P; Yang J; Kresolic Z; Paproski R; Cass C; McEwan AJ; Wiebe LI
    J Pharm Pharm Sci; 2007; 10(2):237-45. PubMed ID: 17706182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and hypoxia-selective cytotoxicity of a 2-nitroimidazole mustard.
    Lee HH; Palmer BD; Wilson WR; Denny WA
    Bioorg Med Chem Lett; 1998 Jul; 8(13):1741-4. PubMed ID: 9873426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro evaluation of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-trifluoromethylquinoline hydrochloride (NLTQ-1), a new bioreductive agent as a hypoxia marker by 19F-magnetic resonance spectroscopy (19F-MRS).
    Papadopoulou MV; Pouremad R; Rao MK; Ji M; Bloomer WD
    In Vivo; 2001; 15(5):365-71. PubMed ID: 11695231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of polyamine homologation on the transport and biological properties of heterocyclic amidines.
    Delcros JG; Tomasi S; Duhieu S; Foucault M; Martin B; Le Roch M; Eifler-Lima V; Renault J; Uriac P
    J Med Chem; 2006 Jan; 49(1):232-45. PubMed ID: 16392808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles.
    Asquith JC; Watts ME; Patel K; Smithen CE; Adams GE
    Radiat Res; 1974 Oct; 60(1):108-18. PubMed ID: 10881704
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthesis and bioevaluation of N-(arylalkyl)-homospermidine conjugates.
    Xie S; Cheng P; Liu G; Ma Y; Zhao J; Chehtane M; Khaled AR; Phanstiel O; Wang C
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4471-5. PubMed ID: 17574415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of nitroimidazole sensitizers and oxygen in the radiosensitization of mammalian cells at ultrahigh dose rates.
    Michaels HB; Ling CC; Epp ER; Peterson EC
    Radiat Res; 1981 Mar; 85(3):567-82. PubMed ID: 7208811
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro.
    Papadopoulou MV; Ji X; Bloomer WD
    Anticancer Res; 2005; 25(3B):2161-70. PubMed ID: 16158959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
    Amin KM; Ismail MM; Noaman E; Soliman DH; Ammar YA
    Bioorg Med Chem; 2006 Oct; 14(20):6917-23. PubMed ID: 16843668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.